Acute Myeloid Leukemia — Many Diseases, Many Treatments
Mené sur une cohorte initiale de 84 patients atteints d'une leucémie myéloïde aiguë ou d'un syndrome myélodysplasique, puis sur une cohorte complémentaire de 32 patients, cet essai identifie les mutations somatiques, dont des mutations du gène P53, associées à la réponse à la décitabine et à la survie globale
Patients with acute myeloid leukemia (AML) generally receive stereotypical treatment.1 For example, young patients receive cytarabine for 7 days and an anthracycline for 3 days (known as “7+3 induction”). Thus treated, some groups, predictably, have an approximately 50% chance of “cure” (“favorable risk”) whereas others, also predictably, have a survival of 6 to 18 months (“unfavorable risk”). This nonrandom heterogeneity after homogeneous treatment suggests that, like pneumonia, AML is several diseases. Today, AML is primarily defined according to leukemia-cell karyotype and an increasing number of molecular aberrations.2 It follows that different types of AML should ideally be treated differently. This . .
New England Journal of Medicine , éditorial, 2015